April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.
March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.
Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
A new study adds to mounting evidence that all people should be screened and offered the vaccine for human papillomavirus.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.